Takeda to consolidate research sites worldwideStaff Writer | August 1, 2016
Takeda Pharmaceutical will consolidate research activities in several countries into the U.S. and Japan, aiming to streamline its drug pipeline.
Pharmaceuticals Takeda Pharma expects 18bn yen in annual cost savings
The bulk of research functions in China's Guangzhou and Brazil's Rio de Janeiro will also move. These steps will increase the number of researchers per site, contributing to a more vigorous exchange of information.
After the reorganization, Takeda's research hubs will be in the U.S. city of Boston and in Fujisawa, near Tokyo, at the Shonan Research Center.
On the development side, Boston will have core responsibility for advancing drug candidates to the product stage and overall planning. It will coordinate with development centers in Japan, the U.S., Europe and elsewhere.
The company sees the steps costing up to 25 billion yen ($244 million) or so in fiscal 2016 and around 50 billion yen in fiscal 2017, including closing laboratories as well as relocating personnel and equipment to Japan and America.
It expects 18 billion yen in annual cost savings after the reorganization is complete. ■